Literature DB >> 20306021

Denosumab-related osteonecrosis of the jaws.

A Kyrgidis, K A Toulis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20306021     DOI： 10.1007/s00198-010-1177-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  10 in total

1.  "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws.

Authors:  Athanassios Kyrgidis; Konstantinos Vahtsevanos
Journal:  Clin Oral Investig       Date:  2009-08-13       Impact factor: 3.573

2.  Osteonecrosis of the jaw in patients receiving oral bisphosphonates.

Authors:  Athanassios Kyrgidis; Konstantinos Vahtsevanos
Journal:  Osteoporos Int       Date:  2009-10-28       Impact factor: 4.507

3.  Osteonecrosis of the jaws induced by anti-RANK ligand therapy.

Authors:  K H Taylor; L S Middlefell; K D Mizen
Journal:  Br J Oral Maxillofac Surg       Date:  2010-04       Impact factor: 1.651

Review 4.  Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

Authors:  A D Anastasilakis; K A Toulis; D G Goulis; S A Polyzos; S Delaroudis; A Giomisi; E Terpos
Journal:  Horm Metab Res       Date:  2009-06-17       Impact factor: 2.936

Review 5.  Factors associated with osteonecrosis of the jaw among bisphosphonate users.

Authors:  Lisa M Hess; Joanne M Jeter; Marge Benham-Hutchins; David S Alberts
Journal:  Am J Med       Date:  2008-06       Impact factor: 4.965

Review 6.  Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

Authors:  Beatrice J Edwards; Mrinal Gounder; June M McKoy; Ian Boyd; Mathew Farrugia; Cesar Migliorati; Robert Marx; Salvatore Ruggiero; Meletios Dimopoulos; Dennis W Raisch; Seema Singhal; Ken Carson; Eniola Obadina; Steve Trifilio; Dennis West; Jayesh Mehta; Charles L Bennett
Journal:  Lancet Oncol       Date:  2008-12       Impact factor: 41.316

Review 7.  Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.

Authors:  Athanassios Kyrgidis; Stefanos Triaridis; Kostantinos Vahtsevanos; Kostantinos Antoniades
Journal:  Expert Rev Anticancer Ther       Date:  2009-08       Impact factor: 4.512

8.  Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Konstantinos Vahtsevanos; Athanassios Kyrgidis; Evgenia Verrou; Eirini Katodritou; Stefanos Triaridis; Charalampos G Andreadis; Ioannis Boukovinas; Georgios E Koloutsos; Zisis Teleioudis; Kyriaki Kitikidou; Panagiotis Paraskevopoulos; Konstantinos Zervas; Konstantinos Antoniades
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

Review 9.  RANKL inhibition for the management of patients with benign metabolic bone disorders.

Authors:  Athanasios D Anastasilakis; Konstantinos A Toulis; Stergios A Polyzos; Evangelos Terpos
Journal:  Expert Opin Investig Drugs       Date:  2009-08       Impact factor: 6.206

Review 10.  Risks and benefits of bisphosphonates.

Authors:  R E Coleman
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640
  10 in total
  18 in total

1.  Methods and Biostatistics: a concise guide for peer reviewers.

Authors:  A Kyrgidis; S Triaridis
Journal:  Hippokratia       Date:  2010-12       Impact factor: 0.471

Review 2.  Treatment of osteoporosis in renal insufficiency.

Authors:  Lydia G Schipper; Hanneke W H A Fleuren; Joop P W van den Bergh; Johan R Meinardi; Bart A J Veldman; Cornelis Kramers
Journal:  Clin Rheumatol       Date:  2015-01-29       Impact factor: 2.980

Review 3.  Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.

Authors:  Yahui Grace Chiu; Christopher T Ritchlin
Journal:  Expert Opin Biol Ther       Date:  2016-11-30       Impact factor: 4.388

Review 4.  Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.

Authors:  Marit D Moen; Susan J Keam
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

5.  Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat.

Authors:  Tara L Aghaloo; Ben Kang; Eric C Sung; Michael Shoff; Matthew Ronconi; Jack E Gotcher; Olga Bezouglaia; Sarah M Dry; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

Review 6.  Androgen deprivation and bone.

Authors:  Jean-Baptiste Lattouf; Hicham Fadlallah; Fred Saad
Journal:  Curr Osteoporos Rep       Date:  2011-03       Impact factor: 5.096

7.  Bone health in nonmetastatic prostate cancer: what's the big deal?

Authors:  J B Lattouf; F Saad
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

Review 8.  Evolving role of bone biomarkers in castration-resistant prostate cancer.

Authors:  Janet E Brown; Sheryl Sim
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

9.  Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

Authors:  Wei-Xiang Qi; Li-Na Tang; Ai-Na He; Yang Yao; Zan Shen
Journal:  Int J Clin Oncol       Date:  2013-04-20       Impact factor: 3.402

Review 10.  New cancer therapies and jaw necrosis.

Authors:  V Patel; M Kelleher; C Sproat; J Kwok; M McGurk
Journal:  Br Dent J       Date:  2015-09-11       Impact factor: 1.626
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.